Last reviewed · How we verify
Metformin continue
Metformin reduces hepatic glucose production and improves insulin sensitivity, thereby lowering blood glucose levels in type 2 diabetes.
Metformin reduces hepatic glucose production and improves insulin sensitivity, thereby lowering blood glucose levels in type 2 diabetes. Used for Type 2 diabetes mellitus, Prediabetes (prevention of progression to type 2 diabetes), Polycystic ovary syndrome (PCOS)-related hyperglycemia.
At a glance
| Generic name | Metformin continue |
|---|---|
| Also known as | Metformin |
| Sponsor | University of Texas Southwestern Medical Center |
| Drug class | Biguanide |
| Target | AMP-activated protein kinase (AMPK); mitochondrial complex I |
| Modality | Small molecule |
| Therapeutic area | Endocrinology/Diabetes |
| Phase | FDA-approved |
Mechanism of action
Metformin is a biguanide that primarily works by decreasing gluconeogenesis in the liver and enhancing peripheral glucose uptake and utilization. It may also improve insulin sensitivity by reducing hepatic fat content and modulating mitochondrial function. The drug does not stimulate insulin secretion, making it weight-neutral and useful across a broad range of patients.
Approved indications
- Type 2 diabetes mellitus
- Prediabetes (prevention of progression to type 2 diabetes)
- Polycystic ovary syndrome (PCOS)-related hyperglycemia
Common side effects
- Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)
- Metallic taste
- Vitamin B12 deficiency
- Lactic acidosis (rare, in renal impairment)
Key clinical trials
- Effect of Short-Term Beta-Cell Rest in Adolescents and Young Adults With Type 2 Diabetes Mellitus
- An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer (PHASE2)
- Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma (PHASE2)
- To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer (PHASE1)
- Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma (PHASE2)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma (PHASE2)
- Liraglutide Effect in Atrial Fibrillation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metformin continue CI brief — competitive landscape report
- Metformin continue updates RSS · CI watch RSS
- University of Texas Southwestern Medical Center portfolio CI